Gilead’s third-quarter results ‘strongest of the year to date’
US biotech major Gilead Sciences (Nasdaq: GILD) was trading nearly 2% higher in pre-market on Thursday after announcing its third-quarter financial results and latest guidance for 2024 as a whole.
The Californian company reported that its total quarterly revenue rose 7% compared to the same period in 2023. The $7.5 billion figure exceeded the predictions of analysts. Those surveyed by Zacks expected $6.99 billion.
On a per-share basis, Gilead said it had diluted earnings per share (EPS) of $1 in the third quarter of 2024, compared to $1.73 in the same period in 2023. The decrease was primarily driven by a pre-tax in-process research and development impairment of $1.75 billion, or $1.04 per share net of tax impact, related to assets acquired by the company from Immunomedics, in 2020, as well as higher acquired IPR&D expense.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze